Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 91 entries
View as:

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04606472 Org: User:
Start: 11/10/20 End: 06/30/25 Due: 06/30/26

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT05054439 Org: User:
Start: 12/22/21 End: 06/30/25 Due: 06/30/26

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT05022654 Org: User:
Start: 12/13/21 End: 06/30/25 Due: 06/30/26

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06978114 Org: User:
Start: 06/30/25 End: 12/31/27 Due: 12/31/28

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT05044897 Org: User:
Start: 10/20/21 End: 06/30/25 Due: 06/30/26

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05924750 Org: User:
Start: 08/02/23 End: 08/31/25 Due: 08/31/26

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06718634 Org: User:
Start: 01/02/25 End: 12/31/27 Due: 12/31/28

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT05020457 Org: User:
Start: 12/07/21 End: 06/30/25 Due: 06/30/26

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06316531 Org: User:
Start: 05/08/24 End: 05/31/26 Due: 05/31/27

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06612840 Org: User:
Start: 10/16/24 End: 10/31/26 Due: 10/31/27

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05949619 Org: User:
Start: 09/04/23 End: 08/31/25 Due: 08/31/26

A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06962787 Org: User:
Start: 05/31/25 End: 12/31/27 Due: 12/31/28

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06718621 Org: User:
Start: 02/12/25 End: 06/30/27 Due: 06/30/28

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05949606 Org: User:
Start: 10/30/23 End: 11/30/25 Due: 11/30/26

Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05668858 Org: User:
Start: 02/10/23 End: 12/31/25 Due: 12/31/26

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06066203 Org: User:
Start: 11/01/23 End: 11/30/25 Due: 11/30/26

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06957886 Org: User:
Start: 05/15/25 End: 12/31/27 Due: 12/31/28

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05160545 Org: User:
Start: 11/26/21 End: 12/31/25 Due: 12/31/26

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06343948 Org: User:
Start: 04/24/24 End: 05/31/26 Due: 05/31/27

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06114511 Org: User:
Start: 04/24/24 End: 04/30/26 Due: 04/30/27

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06006169 Org: User:
Start: 10/20/23 End: 10/31/25 Due: 10/31/26

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05924841 Org: User:
Start: 11/10/23 End: 11/30/25 Due: 11/30/26

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05262491 Org: User:
Start: 02/14/22 End: 12/31/25 Due: 12/31/26

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06031584 Org: User:
Start: 01/19/24 End: 03/31/26 Due: 03/31/27

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06437509 Org: User:
Start: 06/13/24 End: 06/30/26 Due: 06/30/27